Congruence Therapeutics closed a $39.5 million financing round to advance a portfolio of small‑molecule correctors targeting protein‑misfolding diseases into the clinic. The funding follows the company’s move into first‑in‑human testing and builds on the founder’s prior exits and experience in the field. Management said proceeds will support clinical development and IND‑enabling work for lead correctors. Investors framed the round as a bet on precision small‑molecule approaches to address misfolding pathologies, with near‑term milestones tied to early clinical readouts and regulatory engagement.